Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma.

The development was reported about 36 minutes ago. The initial verified report was . The verified report states: ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company.

It also reports: The new site, Intermountain Health LDS Hospital, in Salt. Another confirmed detail is: Estrella expects that data from this expansion cohort will. The available report further notes: As of the date of this press release, active.

A further verified point is: And Intermountain Health LDS Hospital.